市場調查報告書
商品編碼
1466802
真實世界證據解決方案市場:按組成部分、治療領域和最終用戶 - 2024-2030 年全球預測Real World Evidence Solution Market by Component (Data Set, Services), Therapeutic Area (Cardiovascular, Immunology, Infectious Diseases), End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
現實世界證據解決方案市場規模預計到 2023 年為 13.8 億美元,預計到 2024 年將達到 15.6 億美元,到 2030 年將達到 34.7 億美元,複合年成長率為 14.09%。
真實世界證據 (RWE) 解決方案使醫療保健組織、政府機構和製藥公司能夠分析和利用真實世界資料。這些資料包括在傳統臨床試驗之外收集的資訊,例如電子健康記錄(EHR)、保險申請、患者登記和移動設備,以提高日常臨床實踐中醫療保健干預的有效性、安全性和價值。價值。製藥公司加強研發力度,擴大採用 RWE 解決方案來開發具有成本效益的藥物並縮短時間。監管機構越來越認知到 RWE 在了解藥物和設備的上市後使用、推動市場成長的價值。不斷發展的醫療保健行業向基於價值的護理的轉變正在推動 RWE 解決方案的使用來證明治療效果。有關真實世界證據 (RWE) 解決方案的資料隱私和安全問題阻礙了市場成長。開拓先進的分析模型和演算法,從多樣化的大型資料集提取有意義的見解,並建立滿足複雜需求的方便用戶使用平台,預計將成為市場成長的基礎。
主要市場統計 | |
---|---|
基準年[2023] | 13.8億美元 |
預測年份 [2024] | 15.6億美元 |
預測年份 [2030] | 34.7億美元 |
複合年成長率(%) | 14.09% |
擴大資料集在現實世界證據解決方案中的使用,以產生組件現實世界證據 (RWE)
在現實世界證據解決方案中,資料集元件是指可用於產生現實世界證據(RWE)的現實世界資料(RWD)的集合。這些資料集是從可以告知健康狀況的資訊來源收集的,例如索賠和申請活動、電子健康記錄(EHR)、產品和疾病登記、患者產生的資料(包括家庭使用設定)以及行動資訊來源。資料。真實世界證據解決方案的服務組件包括解決方案提供者提供的各種服務,以幫助客戶產生和利用真實世界證據。服務範圍從資料分析和處理到現實世界研究設計和實施的諮詢。其他服務包括監管支援、高級分析、資料解釋和策略規劃,以確保遵守適用的準則。
最終用戶:生物製藥公司擴大使用真實世界的證據解決方案來支持藥物開發。
生物製藥公司依靠 RWE 解決方案來支援藥物開發、打入市場策略和上市後監督。他們需要能夠深入了解患者治療結果、衛生經濟學和流行病學的解決方案。 RWE 對於向監管機構、付款人和醫療保健提供者展示藥品的價值至關重要。這些公司更喜歡強大的資料分析平台,可以處理來自申請資料、電子健康記錄(EHR) 和患者登記的大型資料集。臨床和生命科學組織,包括委外研發機構(CRO) 和學術機構,使用 RWE 來檢驗臨床試驗結果並更好地了解疾病進展和治療途徑。這些使用者重視 RWE 的能力,因為它能夠識別患者群體、加強臨床試驗招募以及建立更有效和更具成本效益的治療通訊協定。他們也正在尋找能夠將臨床試驗資料與真實世界患者資料即時連接的技術。診斷和醫療設備公司擴大採用 RWE 進行產品開發和市場差異化。對於這些公司,RWE 可以為診斷測試和設備的設計和效用提供資訊,監控上市後安全性,並支援報銷和健康技術評估 (HTA) 提交。這些公司優先考慮能夠證明臨床療效和現實世界易用性的解決方案,並提供與現有標準治療的比較分析。
區域洞察
在美洲,隨著醫療改革的措施不斷增加,RWE 解決方案市場正在不斷擴大,從而刺激了利用 RWE 來增強決策的需求。在美洲,與醫療保健領域的高級資料分析和人工智慧相關的專利申請正在迅速增加。對數位醫療技術的投資持續增加,反映出對醫療保健服務創新的追求。在歐盟 (EU),RWE 解決方案的採用情況多種多樣,有些國家比其他國家更先進。在歐洲,對醫療保健干預措施的成本效益和預算影響的日益關注正在推動對 RWE 的需求。中東和非洲是 RWE 解決方案的多元化新興市場,那裡的醫療基礎設施和法律規範的發展速度參差不齊。亞太地區是 RWE 解決方案充滿活力且快速成長的市場,其中中國、日本和印度等國家發揮關鍵作用。中國最新的五年計畫高度重視醫療保健和生物技術,體現了對數位健康和投資萊茵集團的承諾。日本對醫療保健創新的重視體現在國家資助的旨在將 RWE 納入醫療保健服務和藥品監管的舉措中。在印度,數位化的提高、政府在全民健康覆蓋方面的努力以及製藥業的成長正在為萊茵集團的前景做出貢獻。
FPNV定位矩陣
FPNV 定位矩陣對於評估真實世界證據解決方案市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對現實世界證據解決方案市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 真實世界證據解決方案市場的市場規模和預測是多少?
2.在現實世界證據解決方案市場的預測期內,有哪些產品、細分市場、應用程式和領域需要考慮投資?
3.真實世界證據解決方案市場的技術趨勢和法規結構是什麼?
4.現實世界證據解決方案市場主要供應商的市場佔有率是多少?
5. 進入真實世界證據解決方案市場的適當型態和策略手段是什麼?
[199 Pages Report] The Real World Evidence Solution Market size was estimated at USD 1.38 billion in 2023 and expected to reach USD 1.56 billion in 2024, at a CAGR 14.09% to reach USD 3.47 billion by 2030.
The real world evidence (RWE) solutions enable healthcare organizations, government agencies, and pharmaceutical companies to analyze and utilize real-world data. This data, which includes information collected outside of traditional clinical trials such as electronic health records (EHR), insurance claims, patient registries, and mobile devices, is proving to be invaluable for understanding the effectiveness, safety, and value of healthcare interventions in day-to-day clinical practice. The rise in R&D by pharmaceutical companies has led to an increase in the adoption of RWE solutions for cost-effective drug development and shorter time-to-market. Regulatory bodies are increasingly acknowledging the value of RWE in understanding post-market drug and device usage, which encourages market growth. The growing healthcare industry's shift towards value-based care has promoted the use of RWE solutions to demonstrate the effectiveness of treatments. Data privacy & security concerns with real world evidence (RWE) solutions hampers the growth of the market. Developing advanced analytical models and algorithms to extract meaningful insights from diverse and large datasets and creating user-friendly platforms that accommodate complex needs are expected to create a platform for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.38 billion |
Estimated Year [2024] | USD 1.56 billion |
Forecast Year [2030] | USD 3.47 billion |
CAGR (%) | 14.09% |
Component: Growing usage of data set within real world evidence solutions to generate real-world evidence (RWE)
In real-world evidence solutions, the data set component refers to the collection of real-world data (RWD) that can be used to generate real-world evidence (RWE). These data sets are derived from various sources such as claims and billing activities, electronic health records (EHRs), product and disease registries, patient-generated data including in-home-use settings, and data gathered from sources that can inform on health status, such as mobile devices. The services component of real-world evidence solutions encompasses the various offerings provided by solution providers to assist clients in generating and leveraging real-world evidence. Services can range from data analytics and processing to consultation on the design and implementation of real-world studies. Additional services may include regulatory support to ensure compliance with applicable guidelines, advanced analytics, data interpretation, and strategic planning.
End-User: Rising potential of real-world evidence solutions across biopharmaceutical companies to support drug development
Biopharmaceutical companies leverage RWE solutions to support drug development, market access strategies, and post-market surveillance. They need solutions that provide insights into patient outcomes, health economics, and epidemiology. RWE is pivotal in demonstrating the value of drugs to regulators, payers, and healthcare providers. These companies prefer robust data analytics platforms that can handle large datasets from claims data, electronic health records (EHR), and patient registries. Clinical and life sciences organizations such as contract research organizations (CROs) and academic institutions use RWE to validate clinical trial outcomes and to understand disease progression and treatment pathways further. These users value RWE for its ability to identify patient cohorts, enhance recruitment for clinical trials, and establish more effective and cost-efficient treatment protocols. They also look for technologies that can create real-time connections between clinical study data and real-world patient data. Diagnostics & medical device companies are increasingly adopting RWE for product development and market differentiation. For these companies, RWE can inform the design and utility of diagnostics tests and devices, monitor post-marketing safety, and support reimbursement and health technology assessment (HTA) applications. They prioritize solutions that can demonstrate clinical effectiveness and real-world usability and offer comparative analyses against existing standards of care.
Regional Insights
In the Americas, the RWE solutions market is expanding with the growing healthcare reform initiatives that fuel demand to leverage RWE for enhanced decision-making. The Americas has seen a surge in patent filings related to advanced data analytics and AI in healthcare. Investment in digital health technologies continues to climb, reflecting the region's pursuit of innovation in healthcare delivery. In the European Union, the adoption of RWE solutions is heterogeneous, with some countries showing more advancement than others. The Euro-centric focus on cost-effectiveness and budget impact for healthcare interventions drives the demand for RWE. The Middle East and Africa showcase a diverse and emerging market for RWE solutions, where healthcare infrastructure and regulatory frameworks are developing at an uneven pace. The Asia Pacific region is a vibrant and fast-growing market for RWE solutions, with countries such as China, Japan, and India playing significant roles. China's latest five-year plan includes a substantial emphasis on healthcare and biotech, showcasing a commitment to invest in digital health and RWE generation. Japan's focus on healthcare innovation is evident in state-funded initiatives aimed at integrating RWE into healthcare delivery and pharmaceutical regulation. In India, increasing digitalization, government initiatives towards universal health coverage, and a growing pharmaceutical sector contribute to the RWE landscape.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Real World Evidence Solution Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Real World Evidence Solution Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Real World Evidence Solution Market, highlighting leading vendors and their innovative profiles. These include Aetion, Inc., Cardinal Health, Inc., Certara, L.P., Clinerion Ltd, Clinixir Company Limited, Cognizant Technology Solutions Corp., COREVITAS, LLC., Flatiron Health, Inc., ICON PLC, International Business Machines Corporation, IQVIA Inc., ISPOR, Laboratory Corporation of America Holdings, Mercy Technology Services, Optum, Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development, LLC by Thermo Fisher Scientific Inc., Quantzig, SAS Institute, Inc., Syneos Health, TATA Consultancy Services Limited, Turacoz, and United BioSource LLC.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Real World Evidence Solution Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Real World Evidence Solution Market?
3. What are the technology trends and regulatory frameworks in the Real World Evidence Solution Market?
4. What is the market share of the leading vendors in the Real World Evidence Solution Market?
5. Which modes and strategic moves are suitable for entering the Real World Evidence Solution Market?